Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Bacteriophage genomics approach to antimicrobial drug discovery published in Nature Biotechnology

12.01.2004


Identifying the targets that bacterial viruses, or phages, use to halt bacterial growth and then screening against those targets for small molecule inhibitors that attack the same targets provides a unique platform for the discovery of novel antibiotics. Researchers from Montreal-based PhageTech, Inc. describe in the February issue of Nature Biotechnology this novel method for discovering new classes of antibiotics. The article is available on-line today at www.nature.com/nbt/.



"Over the course of evolution, the multitudes of phages that attack bacteria have developed unique proteins that bind to and inactivate (or redirect) critical cellular targets within their prey," said Jing Liu, Ph.D., corresponding author of the publication. "This binding shuts off key metabolic processes in the bacteria, diverting those organisms from their own growth and reproduction to the production of new phage progeny. We believe these phage-identified bacterial "weak spots" will provide useful screening targets for discovering the sorts of truly novel antibiotics needed to combat growing antibiotic resistance."

The publication’s authors used a high-throughput phage genomics strategy to identify novel 31 novel polypeptide families that inhibit Staphylococcus aureus growth when expressed in the bacteria. Several of these were found to attack targets essential for bacterial DNA replication or transcription. They then employed the interaction between a prototypic phage peptide, ORF104 of phage 77, and its bacterial target, DnaI, to screen for small molecule inhibitors. Using this strategy, the researchers found several novel compounds that inhibited both bacterial growth and DNA synthesis.


"This strategy offers several benefits as a novel approach to antimicrobial drug discovery," said Jinzi J. Wu, M.D., Ph.D., PhageTech vice president, R&D - biology. "First, the bacterial targets identified in this manner are evolutionarily validated as important to bacterial growth and potentially susceptible to inactivation by small molecule drugs. This allows us to quickly pinpoint the most promising anti-microbial targets from among thousands of possible candidates. Second, this approach provides a ready-to-use screening assay based on inhibition of interactions between a phage peptide and its bacterial target."

"The fight against growing bacterial resistance requires new classes of antibiotics against novel targets. Our strategy of screening for compounds that address the same antibacterial targets attacked by phages is a very good way of identifying novel compounds against many different bacterial species," concluded Dr Wu.

Applying its novel antibiotic discovery platform, PhageTech has identified eight novel antimicrobial targets against which the company is screening chemical libraries and applying medicinal chemistry to further refine and evaluate those inhibitors. PhageTech has also continued to expand its phage genomics platform from Staphylococcus aureus to other bacterial pathogens including Streptococcus pneumoniae and Pseudomonas aeruginosa.


About PhageTech

PhageTech is a private, venture-backed biopharmaceutical company focused on the discovery and development of new classes of antibiotic drugs for novel antibacterial targets, based on its world-leading efforts in phage genomics. By unraveling the genetic code of phages, or bacterial viruses, PhageTech identified antimicrobial proteins used by the phages to kill or stop the growth of bacteria, as well as the specific bacterial targets with which those proteins interact. The company then screens these bacterial targets to identify novel small molecule drugs that attack the same targets to achieve bacterial growth inhibitory effects. PhageTech is headquartered in Montreal, Québec. For more information on PhageTech, please contact Michel Harpin, director of business development at 514-332-1008.

Contact:

Michel Harpin
Director, Business Development
PhageTech
514-332-1008
mharpin@phagetech.com

Joan Kureczka
Kureczka/Martin Associates
415-821-2413
Jkureczka@aol.com

Joan Kureczka | EurekAlert!
Further information:
http://www.nature.com/nbt/
http://www.phagetech.com

More articles from Life Sciences:

nachricht More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

More genes are active in high-performance maize

19.01.2018 | Life Sciences

How plants see light

19.01.2018 | Life Sciences

Artificial agent designs quantum experiments

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>